Ironwood Pharmaceuticals (IRWD) Cash & Equivalents (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Cash & Equivalents across 17 years of filings, most recently posting $79.1 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 14.78% year-over-year to $79.1 million; the TTM figure through Jun 2026 stood at $79.1 million (down 14.78% YoY), while the FY2025 annual figure was $215.5 million, up 143.29% from the prior year.
• Cash & Equivalents came in at $79.1 million for Q2 2026 at Ironwood Pharmaceuticals, down from $220.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $740.3 million in Q1 2023 to a low of $79.1 million in Q2 2026.
• Average Cash & Equivalents over 5 years is $261.5 million, with a median of $131.0 million recorded in 2024.
• Year-over-year, Cash & Equivalents tumbled 85.96% in 2023 and surged 143.29% in 2025.
• Over 5 years, Cash & Equivalents stood at $656.2 million in 2022, then plunged by 85.96% to $92.2 million in 2023, then retreated by 3.9% to $88.6 million in 2024, then surged by 143.29% to $215.5 million in 2025, then plunged by 63.27% to $79.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $79.1 million in Q2 2026, $220.5 million in Q1 2026, and $215.5 million in Q4 2025.